Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: Implications for heterogeneous accumulation of MIBG;Erratum: Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: Implications for heterogeneous accumulation of MIBG (European Journal of Nuclear Medicine and Molecular Imaging DOI: 10.1007/s00259-004-1694-7)

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 8, 2005, Pages 993-997

  Kiyono, Yasushi ^a   Kajiyama, Satomi ^b   Fujiwara, Hiromi ^b   Kanegawa, Naoki ^b   Saji, Hideo ^b  

^a KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; MIBG; Norepinephrine transporter; Polyol pathway; Sympathetic nervous system

Indexed keywords

ERRATUM; RETRACTED ARTICLE; ADRENERGIC SYSTEM; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HEART; HEART MUSCLE; INNERVATION; MALE; METABOLIC CLEARANCE RATE; METABOLISM; RAT; SCINTISCANNING; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

(3 IODOBENZYL)GUANIDINE; ALDEHYDE REDUCTASE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; POLYMER; POLYOL; RADIOPHARMACEUTICAL AGENT; RHODANINE; SORBITOL; STREPTOZOCIN;

3-IODOBENZYLGUANIDINE; ALDEHYDE REDUCTASE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; HEART; MALE; METABOLIC CLEARANCE RATE; MYOCARDIUM; POLYMERS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RHODANINE; SIGNAL TRANSDUCTION; SORBITOL; STREPTOZOCIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 23944523903     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1694-7     Document Type: Article

References (31)

1. 1. N Hattori M Schwaiger 2000 Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med 27 1 6 1:STN:280:DC%2BD3c7hvFKgtA%3D%3D 10654140 Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med 2000;27:1–6.
2. 2. GA Lanza 1999 Abnormal cardiac nerve function in syndrome X Herz 24 97 106 1:STN:280:DyaK1MzgtVyrsQ%3D%3D 10372295 Lanza GA. Abnormal cardiac nerve function in syndrome X. Herz 1999;24:97–106.
3. 3. P Merlet H Valette JL Dubois-Rande K Mardon F Pouillart ML Bourachot 1994 Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease J Nucl Cardiol 1 S79 85 1:STN:280:DyaK1c%2Fot1aksA%3D%3D 9420702 Merlet P, Valette H, Dubois-Rande JL, Mardon K, Pouillart F, Bourachot ML, et al. Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease. J Nucl Cardiol 1994;1:S79–85.
4. 4. N Hattori N Tamaki T Hayashi I Masuda T Kudoh M Tateno 1996 Regional abnormality of iodine-123-MIBG in diabetic hearts J Nucl Med 37 1985 90 1:STN:280:ByiC38rksVY%3D 8970519 Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med 1996;37:1985–90.
5. 5. G Kreiner M Wolzt P Fasching T Leitha A Edlmayer A Korn 1995 Myocardial m-[ 123 I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function Diabetes 44 543 9 1:CAS:528:DyaK2MXlsF2gt7Y%3D 7729613 Kreiner G, Wolzt M, Fasching P, Leitha T, Edlmayer A, Korn A, et al. Myocardial m-[ 123 I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 1995;44:543–9.
6. 6. A Langer MR Freeman RG Josse PW Armstrong 1995 Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia J Am Coll Cardiol 25 610 8 1:STN:280:ByqC28vos1Y%3D 7860904 Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995;25:610–8.
7. 7. O Schnell CM Kirsch J Stemplinger M Haslbeck E Standl 1995 Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy Diabetologia 38 1345 52 1:STN:280:BymC2cjgtF0%3D 8582545 Schnell O, Kirsch CM, Stemplinger J, Haslbeck M, Standl E. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia 1995;38:1345–52.
8. 8. S Yagihashi SI Yamagishi R Wada Ri M Baba TC Hohman C Yabe-Nishimura 2001 Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor Brain 124 2448 58 1:STN:280:DC%2BD3MnovFKitA%3D%3D 11701599 Yagihashi S, Yamagishi SI, Wada Ri R, Baba M, Hohman TC, Yabe-Nishimura C, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001;124:2448–58.
9. 9. NE Cameron MA Cotter M Basso TC Hohman 1997 Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats Diabetologia 40 271 81 1:CAS:528:DyaK2sXhs1Ckt7k%3D 9084964 Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997;40:271–81.
10. 10. DA Greene AA Sima MJ Stevens EL Feldman PD Killen DN Henry 1993 Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage Diabetes Metab Rev 9 189 217 1:STN:280:ByuB2cvktlw%3D 8187607 Greene DA, Sima AA, Stevens MJ, Feldman EL, Killen PD, Henry DN, et al. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 1993;9:189–217.
11. 11. Y Kiyono Y Iida H Kawashima N Tamaki H Nishimura H Saji 2001 Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes Eur J Nucl Med 28 894 9 1:CAS:528:DC%2BD3MXkvVWltLc%3D 11504086 Kiyono Y, Iida Y, Kawashima H, Tamaki N, Nishimura H, Saji H. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur J Nucl Med 2001;28:894–9.
12. 12. Y Kiyono Y Iida H Kawashima M Ogawa N Tamaki H Nishimura 2002 Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats Eur J Nucl Med Mol Imaging 29 999 1005 1:CAS:528:DC%2BD38Xls12gu7w%3D 12173012 Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 2002;29:999–1005.
13. 13. DA Greene JC Arezzo MB Brown 1999 Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group Neurology 53 580 91 1:CAS:528:DyaK1MXlsleisrw%3D 10449124 Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53:580–91.
14. 14. JI Malone G Knox S Benford TA Tedesco 1980 Red cell sorbitol: an indicator of diabetic control Diabetes 29 861 4 1:CAS:528:DyaL3MXkt1ant78%3D 7429027 Malone JI, Knox G, Benford S, Tedesco TA. Red cell sorbitol: an indicator of diabetic control. Diabetes 1980;29:861–4.
15. 15. M Haaparanta R Paul R Huovinen H Kujari J Bergman O Solin 1995 Pharmacokinetics and metabolism of 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG) in mammary tumors of antiestrogen-treated rats Nucl Med Biol 22 483 9 1:CAS:528:DyaK2MXntVamsLg%3D 7550025 Haaparanta M, Paul R, Huovinen R, Kujari H, Bergman J, Solin O, et al. Pharmacokinetics and metabolism of 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG) in mammary tumors of antiestrogen-treated rats. Nucl Med Biol 1995;22:483–9.
16. 16. OH Lowry NJ Rosebrough AL Farr RJ Randall 1951 Protein measurements with the folin phenol reagent J Biol Chem 193 265 75 1:CAS:528:DyaG38XhsVyrsw%3D%3D 14907713 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem 1951;193:265–75.
17. 17. D Finegold SA Lattimer S Nolle M Bernstein DA Greene 1983 Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy Diabetes 32 988 92 1:CAS:528:DyaL2cXkt1yh 6416910 Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 1983;32:988–92.
18. 18. JA Mayhew KR Gillon JN Hawthorne 1983 Free and lipid inositol, sorbitol and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects Diabetologia 24 13 15 1:STN:280:BiyC3s3pvVM%3D 6825977 Mayhew JA, Gillon KR, Hawthorne JN. Free and lipid inositol, sorbitol and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 1983;24:13–15.
19. 19. DA Greene S Lattimer-Greene AA Sima 1989 Pathogenesis of diabetic neuropathy: role of altered phosphoinositide metabolism Crit Rev Neurobiol 5 143 219 1:STN:280:By%2BA28%2FktFE%3D 2561904 Greene DA, Lattimer-Greene S, Sima AA. Pathogenesis of diabetic neuropathy: role of altered phosphoinositide metabolism. Crit Rev Neurobiol 1989;5:143–219.
20. 20. X Zhu J Eichberg 1990 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in sciatic nerve from streptozotocin-induced diabetic rats J Neurochem 55 1087 90 1:CAS:528:DyaK3cXmtV2htLk%3D 2117050 Zhu X, Eichberg J. 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in sciatic nerve from streptozotocin-induced diabetic rats. J Neurochem 1990;55:1087–90.
21. 21. AA Sima T Brismar 1985 Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities Ann Neurol 18 21 29 1:STN:280:BiqA3crlslc%3D 3898998 Sima AA, Brismar T. Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities. Ann Neurol 1985;18:21–29.
22. 22. MJ Stevens EL Feldman DA Greene 1995 The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects Diabet Med 12 566 79 1:STN:280:BymD38vhtVw%3D 7554777 Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med 1995;12:566–79.
23. 23. R Ramasamy PJ Oates S Schaefer 1997 Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury Diabetes 46 292 300 1:CAS:528:DyaK2sXmtlyktw%3D%3D 9000707 Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997;46:292–300.
24. 24. SG Amara MJ Kuhar 1993 Neurotransmitter transporters: recent progress Annu Rev Neurosci 16 73 93 1:CAS:528:DyaK3sXktVSqur8%3D 8096377 Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73–93.
25. 25. K Addicks C Boy P Rosen 1993 Sympathetic autonomic neuropathy in the heart of the spontaneous diabetic BB rat Ann Anat 175 253 7 1:STN:280:ByyA3s3itlw%3D 8338224 Addicks K, Boy C, Rosen P. Sympathetic autonomic neuropathy in the heart of the spontaneous diabetic BB rat. Ann Anat 1993;175:253–7.
26. 26. DA Greene AA Sima MJ Stevens EL Feldman SA Lattimer 1992 Complications: neuropathy, pathogenetic considerations Diabetes Care 15 1902 25 1:STN:280:ByyD1MbnslA%3D 1464245 Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992;15:1902–25.
27. 27. AI Vinik MT Holland JM Le Beau FJ Liuzzi KB Stansberry LB Colen 1992 Diabetic neuropathies Diabetes Care 15 1926 75 1:STN:280:ByyD1MbnslE%3D 1464246 Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care 1992;15:1926–75.
28. 28. NE Cameron MA Cotter 2002 Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism Diabetes Metab Res Rev 18 315 23 1:CAS:528:DC%2BD38Xot1Wlu7c%3D 12203947 Cameron NE, Cotter MA. Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 2002;18:315–23.
29. 29. S Apparsundaram A Galli LJ DeFelice HC Hartzell RD Blakely 1998 Acute regulation of norepinephrine transport. I. Protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells J Pharmacol Exp Ther 287 733 43 1:CAS:528:DyaK1cXnsVertbc%3D 9808704 Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC, Blakely RD. Acute regulation of norepinephrine transport. I. Protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther 1998;287:733–43.
30. 30. S Apparsundaram S Schroeter E Giovanetti RD Blakely 1998 Acute regulation of norepinephrine transport. II. PKC-modulated surface expression of human norepinephrine transporter proteins J Pharmacol Exp Ther 287 744 51 1:CAS:528:DyaK1cXnsVerur4%3D 9808705 Apparsundaram S, Schroeter S, Giovanetti E, Blakely RD. Acute regulation of norepinephrine transport. II. PKC-modulated surface expression of human norepinephrine transporter proteins. J Pharmacol Exp Ther 1998;287:744–51.
31. 31. SG Amara MS Sonders NR Zahniser SL Povlock GM Daniels 1998 Molecular physiology and regulation of catecholamine transporters Adv Pharmacol 42 164 8 1:CAS:528:DyaK2sXntFWqurY%3D 9327869 Amara SG, Sonders MS, Zahniser NR, Povlock SL, Daniels GM. Molecular physiology and regulation of catecholamine transporters. Adv Pharmacol 1998;42:164–8.